Fortress Doesn’t Believe in (Possibly Care About) Conflict Checks

“NY Post – SoftBank’s Fortress Investment Group is raising a $400 million fund to sue tech companies over intellectual property infringement…”

Before we get started, I know that Mike Novogratz left his life’s work years ago, but who else am I going to put up there to represent Fortress?

Now, I have to admit I was ready to poke some fun at SoftBank for this one. How can a conglomerate, with telecom, semiconductor and robotics interests allow one of its portfolio companies to be an outright patent troll? How can SoftBank, who has $195B in committed capital for it’s tech-focused investment vehicles, allow Fortress (“FIG”) to shakedown the very companies in which they seek to invest? Well after a while, it hit me: whether purposeful or not, this is probably a great way to hedge a tech-centric private equity portfolio. Outside of proper due diligence, managing FX / rates exposure or structuring capital calls to meet specific milestones, there aren’t many ways to manage the downside risk of making poor investments in the first place – especially when deploying capital into intellectual property-heavy tech industry.

Odds are, you’re investing in a tech company because it claims to have a new technology that can streamline business processes, enhance end-user experiences or is simply a brand new class of product. With new technology comes the prospect of a high adoption rate and, of course, multiples of invested capital. It’s not all glitz and glamour though, and there are real risks to investing in the tech space, more so perhaps than any other industry. The costliest mistake you can make in tech investing is, by a wide margin, not conducting the proper diligence around a target’s intellectual property / patent portfolio. Does the company really own this IP? Are they infringing on someone else’s IP? Who’s line of code is this, truly? Are there any outstanding lawsuits? What about imminent filings? Tons of these lawsuits are filed every day around the world by what are known as “patent trolls” – individuals or funds that buy random portfolios of IP and lawyer up to shakedown other tech companies for infringement. Rarely do the lawsuits reach a decision as they’re usually settled outside of court, which is exactly what the patent troll wanted. It’s a pretty scummy industry, but it’s also pretty lucrative – which is why FIG wants a piece of it. If a respected NYC asset manager raises $400M with the intention of suing nerdy Silicon Valley idealists into oblivion, the nerds will pay up to settle. Cash burn is fine when it serves whatever “mission” the unicorn de jour says it has, not when it’s being wasted on lawyers.

That brings us to the impact of this new FIG vehicle on its parent, SoftBank. Taken at face value, it seems like FIG is raising two birds toward everything SoftBank has built it’s reputation on – investing in and building out new technologies. If you take a forest vs. tree view, though, a successful patent troll investment platform can hedge against IP-related losses SoftBank portfolio companies may incur. Obviously a $400M investment is an irrelevant hedge for a $195B portfolio, but it’s a start. It’s not unthinkable that were this initial foray to be successful, that FIG would double or triple down to target more or larger targets. I also wouldn’t discount the idea of SoftBank seeding a larger IP strategy within FIG were they to succeed with this initial vehicle – that would be something special. This will be an interesting story to follow in the next few years and, no matter what happens, it’ll be a great exercise in thinking outside of the risk management box for SoftBank.

Here’s The Mooch Getting Spiritual After Missing Out on $100M Payday

Let me start out by saying my firm has blocked Leveraged Burnout on our network, so I’m blogging from my phone. Apologies if there are typos, rambling sentences or any weird formatting issues.

“Bloomberg – HNA Group Co. and SkyBridge Capital have agreed to drop the Chinese conglomerate’s plan to acquire the investment firm.

Anthony Scaramucci: everyone’s favorite hedge fund giant and real life short guy. There was a time when The Mooch had it all. After a bunch of fundraising for then-presidential candidate Trump, he was finally offered the position of White House Director of Communications after the Sean Spicer experiment.  As is normal for cabinet members, he began to divest of assets that could conflict with his duties as a cabinet member, in this case, his stake in the well known fund-of-funds he built, SkyBridge Capital (actually a solid shop, did business with them at one point). The deal was valued at $180M, which would net Scaramucci about $100M at closing.

Anyway, he oddly chose to sell the firm to HNA, a giant Chinese conglomerate, and subject the transaction to CFIUS (which is a council that decides to approve or deny material foreign investments into U.S. companies). This was pretty dumb because after all the Trump-China campaign rhetoric, The Mooch decided to sell out to the Chinese tax free in front of the whole world. Predictably, the whole thing became a drawn out mess because of how high profile the sale was. It also didn’t help that he told a reporter what he really thinks about Steve Bannon and Reince Priebus, leading to him being unceremoniously (but hilariously) fired after 10 days in office.

Welp, that all leads us to yesterday’s developments, where SkyBridge and HNA decided the CFIUS process was too laborious and expensive and moved to kill the deal. So now The Mooch is out $100M and will be returning to the firm he built, which I suppose isn’t the worst thing. Maybe he’ll do the right thing and give Gary Cohn a job, too.

P.S. – Tell me this guy’s tenure at the White House didn’t play out exactly like you thought it would.

Walmart Buying Companies Because Its Competitors Are

Healthcare is an interesting space right now. It seems everyone can feel that change is coming, but nobody actually knows how it’ll materialize. This has resulted in a wave of product announcements and M&A activity from companies that want a piece of the lucrative, yet complex, healthcare pie, and yesterday was no different:

“Bloomberg – Walmart Inc. is in talks with health insurer Humana Inc. for a closer partnership to provide health care to consumers at home and prevent illness, according to a person familiar with the matter.”

News broke last evening that Walmart is in talks with Humana about a much deeper partnership, and possibly an outright acquisition of the insurance company. This is a reactionary deal from Walmart on the heels of the CVS / Aetna transaction, which was a reactionary deal to Amazon entering the space – and that, my friends, is really what this is all about: Jeff Bezos and Amazon’s healthcare ambitions. The Company has announced a healthcare partnership with J.P. Morgan / Berkshire Hathaway, as well as intentions to pursue its own internal initiatives. Amazon has been tight-lipped on their approach, but it is widely assumed they’re going after the pharmaceutical distribution channel, a likely target given Amazon’s logistical and distribution expertise. This would not be welcomed news for companies like Express Scripts (who was acquired by insurer Cigna earlier this month), who manage pharmaceutical benefit plans on behalf of employers by negotiating drug prices with pharmacies and processing claims payments. Amazon would look to put the screws to these middlemen by applying their tried-and-true business model of undercutting on price and over-delivering on service. Amazon will succeed here, as it always does. The issue for pharmacy companies (Walmart, CVS) is to figure out a way to bypass being forced into business with Amazon as they enter the space. Their answer? Buy the insurance companies and handle the middleman activities in-house, building out an entire healthcare network under one roof for their millions of loyal customers. It really isn’t a bad idea and probably one of the best responses to Amazon encroachment I’ve seen. The only hurdles outside of regulatory burden will be sourcing adequately-priced deals and how to pay for them. CVS decided to go the debt route and the markets have been less than pleased. It’ll be interesting to see how it plays out, but I’ve got my chips on Jeff being the most disruptive new entrant into the space.